Avandia is all about cardiovascular risk. The India trial has nothing to do with cardiovascular risk, but damaged samples. Viaject is regular human insulin and no cardiovascular risk problems since it's been out since 1978. Totally different issue. Avandia will have no bearing on Viaject review. I have more data on the issue, but not worth posting...basically not an issue.